BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
Accessnewswire·2026-01-26 08:05
Core Insights - BioNxt Solutions Inc. has made significant progress in its proprietary cladribine oral thin film (ODF) program, achieving a greater than 40% improvement in bioavailability compared to conventional formulations [1] Company Developments - The recent study results represent a key development milestone for the company, supporting its transition toward human clinical evaluation [1]